In situ assay for RNA decapping in tumors
Award amount
$149,051Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VIVID TECHNOLOGIES INC
- Proposal award date
- 2018-03-01
- Contract end date
- 2020-02-29
- UEI
- DP9ZTZNNGDE7
- Solicitation number
- PA16-302
- Topic code
- 102
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In situ assay for topoisomerase 2-mediated DNA damage
- New specific and rapid assay for in situ apoptosis labeling for cancer studies
- Nanocapsule-mediated topical delivery of VLP-generating Dengue DNA vaccine
- In situ assay for DNA cleavage by topoisomerase II
- PEI-somes and cationization of protein probes for microimaging of nervous system
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
8 SBIR/STTR records share this UEI (2007–2021). Reported award amounts total $1,557,288. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services